Key Points {#FPar1}
==========

A prospective observational study was conducted in Japan to investigate the effectiveness and safety of silodosin in patients with benign prostatic hyperplasia.Silodosin showed favorable safety profiles and significant improvement in Japanese patients, including International Prostate Symptom Scores, quality of life scores and Overactive Bladder Symptom Scores.

Introduction {#Sec1}
============

Silodosin (Urief^®^, Kissei Pharmaceutical Co. Ltd. and Daiichi Sankyo Co. Ltd.) is a selective α~1A~ blocker developed in Japan and has been on the market since May 2006. Two post-marketing surveys (a drug use results survey \[[@CR1]\] and a specified drug use results survey \[[@CR2]\]) were conducted after launch, followed by the submission of a reexamination application in April 2014, and the results were reported in June 2015.

The number of patients with benign prostatic hyperplasia (BPH) is expected to increase in Japan, which is becoming a super-aging society. As a result, physicians will be seeing more patients with BPH with age-related progression of symptoms and prolonged periods of treatment and will need to select the optimal drug based on the background of each individual patient. Currently in Japan, α~1~ blockers, including silodosin, are recommended in the Clinical Guidelines for BPH in Japan as a first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH \[[@CR3]\], but selection of an α~1~ blocker depends on the preference of each physician. Furthermore, clinical evidence about switching between α~1~ blockers is currently limited.

A pooled analysis of the earlier post-marketing surveys \[[@CR1], [@CR2]\] with silodosin included an assessment of patients with a treatment history of α~1~ blockers other than silodosin and a low degree of satisfaction (quality of life (QOL) score ≥ 3 points) who switched to silodosin \[[@CR4]\]. The results suggested that the voiding symptom score of the International Prostate Symptom Score (IPSS) was an influential factor on the effectiveness of silodosin in LUTS associated with BPH.

SPLASH ([S]{.ul}tudy on [p]{.ul}atients' QO[L]{.ul} by ch[a]{.ul}nging medication to [s]{.ul}ilodosin in men with BP[H]{.ul}) was a post-marketing surveillance study designed to identify an appropriate patient profile for switching to silodosin. It was a prospective observational study to complement the pooled analysis of the two earlier post-marketing surveys and included the Overactive Bladder Symptom Score (OABSS) in addition to the IPSS and QOL score evaluations included in the previous analyses.

The survey was conducted in accordance with good post-marketing study practice in Japan.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

The study population was selected from among patients with BPH who had not experienced satisfactory outcomes with α~1~ blockers other than silodosin in routine clinical practice and according to the following inclusion criteria: patients who (1) had not received silodosin previously, (2) gave consent to change their medication from their current α~1~ blocker to silodosin, (3) had been using another α~1~ blocker other than silodosin for at least 3 months and (4) were evaluated using the face scale questionnaire before the start of silodosin administration. Exclusion criteria were patients who (1) had a QOL score of ≤ 2 before the start of silodosin administration and/or (2) had started treatment with a 5α-reductase inhibitor within 6 months before the start of silodosin administration.

Patients were enrolled using a prospective central registration method through an online system. The enrollment period was for 1 year from 1 November 2014 to 31 October 2015, and the observation period was set for 3 months. The targeted number of patients for the survey was 3000.

Survey Items {#Sec4}
------------

Basic information collected in the study included patient background, administration status of silodosin, and drug therapy history for LUTS other than silodosin (including prior or concomitant therapies).

Patients were also asked to complete a symptoms checklist before the start of administration and at 3 months after the start of administration (or at the final evaluation) so we could understand the patients' LUTS. The IPSS, the QOL score, and the OABSS were obtained through the symptoms checklist. In addition, residual urine volume was measured before the start of administration and at 3 months after the start of administration (or at the final evaluation) as an objective outcome measure.

Safety data collected in the study included the occurrence of adverse events (AEs) and the likely causal relationship with silodosin in the case of onset of an AE.

Statistical Analysis {#Sec5}
--------------------

Baseline demographic and clinical information was summarized using descriptive summary statistics, including frequency for categorical variables and mean ± standard deviation (SD) for continuous variables.

For the safety assessment, the incidence of adverse drug reactions (ADRs), defined as AEs for which a causal relationship with silodosin could not be ruled out, was calculated for the whole cohort and in specific patient subgroups based on background factors. ADRs were classified according to the preferred terms in the Medical Dictionary for Regulatory Activities-Japanese, version 19.0.

Effectiveness was assessed as the change from baseline in the overall cohort and in subgroups based on the α~1~ blocker (tamsulosin or naftopidil) administered prior to silodosin.

The impact of background factors on the incidence of ADRs was assessed using the chi-squared test and Fisher's exact test, depending on the data properties. To compare the effectiveness measurements before and after administration, a one-sample *t*-test was used. The two-tailed significance level was set at 5%.

Results {#Sec6}
=======

Case Description {#Sec7}
----------------

Figure [1](#Fig1){ref-type="fig"} shows the patient disposition in the study. A total of 3470 case report forms were obtained from 715 medical facilities across Japan. Of those, 115 cases were excluded for reasons such as breach of contract, non-evaluable AEs, enrollment violations, and previous use of silodosin, leaving 3355 cases for the safety analyses. An additional 211 patients were excluded (not meeting inclusion criteria, meeting exclusion criteria, and other), leaving 3144 patients for the effectiveness analyses.Fig. 1Patient disposition. ^†^Patients may be included more than once if they were excluded for more than one reason. ^‡^Patients who received silodosin outside the contract period. ^§^Patients who were not registered within the registration period

Patient Background {#Sec8}
------------------

Baseline demographics and clinical characteristics of the patients in the safety cohort (*n* = 3355) are shown in Table [1](#Tab1){ref-type="table"}. Most patients (46.1%) were aged ≥ 70 and \< 80 years, and the mean age was 73.1 ± 8.2 years. The disease duration with the highest proportion was ≥ 3 years (48.9%). The most administered α~1~ blockers before silodosin were tamsulosin (53.6%) and naftopidil (45.5%), and other concomitant drugs used to treat LUTS included 5α-reductase inhibitor (9.9%), anticholinergics (8.5%), β~3~ agonist (7.0%) and phosphodiesterase 5 (PDE5) inhibitor (2.1%). Based on the total IPSS, most patients had moderate (56.1%) or severe (31.9%) symptoms, with only 8.4% having mild symptoms, and the mean total IPSS was 16.6 ± 6.7. The QOL score showed moderate or severe impairment in 63.3% and 33.6% of patients, respectively, and the mean QOL score was 4.2 ± 0.9. Total OABSS scores were in the mild category for 51.5% of patients, moderate for 40.2%, and severe for 4.0%, with a mean total OABSS of 5.6 ± 3.0.Table 1Baseline demographics and clinical characteristics (safety analysis set)Items and categoriesPatients^a^ (*n* = 3355)Age (years) \< 5014 (0.4) ≥ 50 and \< 60166 (4.9) ≥ 60 and \< 70871 (26.0) ≥ 70 and \< 801545 (46.1) ≥ 80759 (22.6) Non-elderly patients: \< 65485 (14.5) Elderly patients: ≥ 652870 (85.5) Mean ± SD73.1 ± 8.2BMI (kg/m^2^) \< 18.585 (2.5) ≥ 18.5 and \< 25.01339 (39.9) ≥ 25.0 and \< 30.0546 (16.3) ≥ 30.046 (1.4) Unknown/unlisted1339 (39.9) Mean ± SD23.45 ± 3.05Prostate volume (mL) \< 401881 (56.1) ≥ 401083 (32.3) Unknown/unlisted391 (11.7) Mean ± SD38.42 ± 20.19BPH duration \< 3 months15 (0.4) ≥ 3 months and \< 1 year612 (18.2) ≥ 1 year and \< 3 years945 (28.2) ≥ 3 years1640 (48.9) Unknown/unlisted143 (4.3)PSA (ng/mL) ≤ 4.02305 (68.7) \> 4.0 and ≤ 10.0659 (19.6) \> 10.093 (2.8) Unknown/unlisted298 (8.9) Mean ± SD3.377 ± 16.940Complications No1235 (36.8) Yes^b^2117 (63.1) Hypertension1263 (37.6) Dyslipidemia476 (14.2) Diabetes mellitus415 (12.4) Gout38 (1.1) Hyperuricemia181 (5.4) Heart disorder314 (9.4) Unknown/unlisted3 (0.1)α~1~ Blockers used before silodosin Tamsulosin1799 (53.6) Naftopidil1525 (45.5) Other19 (0.6)Concomitant drugs for LUTS other than α~1~ blockers No2195 (65.4) Yes^b^1160 (34.6) Anticholinergics285 (8.5) 5α-Reductase inhibitor331 (9.9) PDE5 inhibitor69 (2.1) β~3~ Agonist234 (7.0)Total IPSS Mild: 0--7281 (8.4) Moderate: 8--191883 (56.1) Severe: 20--351070 (31.9) Mean ± SD16.6 ± 6.7QOL score Mild: 0--11 (0.0) Moderate: 2--42125 (63.3) Severe: 5--61128 (33.6) Mean ± SD4.2 ± 0.9Total OABSS Mild: ≤ 51728 (51.5) Moderate: 6--111349 (40.2) Severe: ≥ 12134 (4.0) Mean ± SD5.6 ± 3.0Residual urine volume (mL) \< 501361 (40.6) ≥ 50 and \< 100497 (14.8) ≥ 100332 (9.9) Unknown/unlisted1165 (34.7) Mean ± SD52.4 ± 64.7*BMI* body mass index, *BPH* benign prostatic hyperplasia, *IPSS* International Prostate Symptom Score, *LUTS* lower urinary tract symptoms, *OABSS* Overactive Bladder Symptom Score, *PDE* phosphodiesterase, *PSA* prostate-specific antigen, *QOL* quality of life, *SD* standard deviation^a^Data are presented as n (%) or mean ± SD^b^Patients may be included more than once if they had more than one condition or were taking more than one concomitant medication

Safety {#Sec9}
------

### Incidence of Adverse Drug Reactions (ADRs) {#Sec10}

The overall incidence of ADRs and those that occurred in five or more patients are described in Table [2](#Tab2){ref-type="table"}. Of the 3355 patients included in the safety analysis, 271 patients developed an ADR (8.1%). ADRs occurring in ≥ 0.5% of patients included ejaculation disorder (1.5%), retrograde ejaculation (1.4%), diarrhoea (1.0%), dizziness (0.9%), and nasal congestion (0.5%).Table 2Incidence of adverse drug reactionsADRsSafety analysis set (*n* = 3355)Number of patients developing ≥ 1 ADR271Number of ADRs reported306Incidence of ADRs (%)8.1Specific ADRs occurring in ≥ 5 patients, *n* (%) Ejaculation disorder52 (1.5) Retrograde ejaculation47 (1.4) Diarrhoea35 (1.0) Dizziness31 (0.9) Nasal congestion18 (0.5) Faeces soft13 (0.4) Dizziness postural11 (0.3) Thirst7 (0.2) Abdominal discomfort6 (0.2) Pollakiuria6 (0.2) Orthostatic hypotension5 (0.1) Urinary incontinence5 (0.1)*ADRs* adverse drug reactions

### Serious ADRs {#Sec11}

Two patients developed serious ADRs: haematemesis (*n* = 1) and urinary retention (*n* = 1). The patient with haematemesis died, and the investigator physician could not determine whether this was causally related to silodosin as the details of the death were unspecified. The urinary retention resolved after transurethral resection of the prostate; the investigator physician determined the causal relationship with silodosin as "unlikely".

### Incidence of ADRs Based on Patient Background Factors {#Sec12}

The incidence of ADRs based on patient background factors is described in Table [3](#Tab3){ref-type="table"}. The age-specific incidence of ADRs was 17.1% in non-elderly (aged \< 65 years) and 6.6% in elderly (aged ≥ 65 years) patients, with a significant difference between groups (*P* \< 0.0001). The incidence of ADRs did not differ significantly between patients who used concomitant drugs for LUTS other than α~1~ blockers (7.6%) and those who did not (8.3%; *P* = 0.4644). Among patients who were taking concomitant therapy for LUTS, ADRs occurred in 7.7% of those taking anticholinergics, 6.9% of those taking a 5α-reductase inhibitor, 10.1% of those taking a PDE5 inhibitor, and 5.6% of those taking a β~3~ agonist.Table 3Incidence of adverse drug reactions in patient subgroups according to background factorsItems and categories*n*ADRs, n (%)*p* valueAll patients3355271 (8.1)Age (years) \< 50143 (21.4)\< 0.0001 (Chi-squared) ≥ 50 and \< 6016636 (21.7) ≥ 60 and \< 70871104 (11.9) ≥ 70 and \< 801545102 (6.6) ≥ 8075926 (3.4) Non-elderly patients: \< 6548583 (17.1)\< 0.0001 (Fisher) Elderly patients: ≥ 652870188 (6.6)Concomitant drugs for LUTS other than α~1~ blockers No2195183 (8.3) 0.4644 (Fisher) Yes116088 (7.6)  Anticholinergics28522 (7.7)  5α-Reductase inhibitor33123 (6.9)  PDE5 inhibitor697 (10.1)  β~3~ Agonist23413 (5.6)*ADR* adverse drug reaction, *LUTS* lower urinary tract symptoms, *PDE* phosphodiesterase

Effectiveness {#Sec13}
-------------

### Improvement in International Prostate Symptom Score (IPSS) {#Sec14}

Overall, 1972--2510 patients in the effectiveness analysis set (*n* = 3144) had data for each symptom of the IPSS before and after the administration of silodosin, and the value for those symptoms was not 0 (Table [4](#Tab4){ref-type="table"}). The mean total IPSS value before silodosin administration was 16.6 ± 6.7 but improved to 12.5 ± 6.4 after silodosin treatment (*P* \< 0.0001). The voiding symptom score, the storage symptom score, and seven other symptoms in the IPSS questionnaire also showed significant improvements with silodosin treatment (*P* \< 0.0001). Significant improvements in the mean total IPSS and all IPSS subscale scores were seen during silodosin therapy, regardless of whether patients had been receiving tamsulosin or naftopidil (*P* \< 0.0001) prior to switching to silodosin.Table 4Changes in IPSS, QOL score, OABSS, and residual urine volume before and after silodosin administrationItemsAll patientsα~1~ Blockers used prior to administration of silodosinTamsulosinNaftopidil*n*Before\
administrationAfter\
administrationChange*p* value^a^*n*Before\
administrationAfter\
administrationChange*p* value^a^*n*Before\
administrationAfter\
administrationChange*p* value^a^Total IPSS251016.6 ± 6.712.5 ± 6.4− 4.1 ± 6.0\< 0.0001135616.5 ± 6.812.3 ± 6.6− 4.2 ± 6.2\< 0.0001114716.8 ± 6.512.7 ± 6.3− 4.1 ± 5.7\< 0.0001IPSS voiding symptoms score^b^24597.7 ± 3.75.8 ± 3.7− 2.0 ± 3.4\< 0.000113277.7 ± 3.85.7 ± 3.7− 2.0 ± 3.5\< 0.000111257.7 ± 3.75.8 ± 3.6− 1.9 ± 3.3\< 0.0001IPSS storage symptoms score^c^24956.9 ± 3.15.3 ± 2.8− 1.6 ± 2.7\< 0.000113446.8 ± 3.25.2 ± 2.8− 1.7 ± 2.8\< 0.000111447.0 ± 3.15.4 ± 2.8− 1.6 ± 2.5\< 0.0001 Incomplete emptying21582.6 ± 1.51.8 ± 1.3− 0.7 ± 1.5\< 0.000111582.5 ± 1.41.8 ± 1.3− 0.7 ± 1.5\< 0.00019952.6 ± 1.51.9 ± 1.3− 0.7 ± 1.5\< 0.0001 Frequency23672.7 ± 1.42.1 ± 1.3− 0.6 ± 1.4\< 0.000112782.7 ± 1.42.1 ± 1.3− 0.6 ± 1.5\< 0.000110842.7 ± 1.42.2 ± 1.3− 0.6 ± 1.4\< 0.0001 Intermittency21252.7 ± 1.52.0 ± 1.5− 0.7 ± 1.5\< 0.000111482.7 ± 1.52.0 ± 1.5− 0.6 ± 1.6\< 0.00019702.7 ± 1.52.0 ± 1.4− 0.7 ± 1.5\< 0.0001 Urgency20702.3 ± 1.41.7 ± 1.3− 0.6 ± 1.4\< 0.000111122.3 ± 1.41.6 ± 1.3− 0.6 ± 1.5\< 0.00019522.3 ± 1.41.7 ± 1.2− 0.6 ± 1.4\< 0.0001 Weak stream24263.4 ± 1.42.5 ± 1.5− 0.9 ± 1.6\< 0.000113103.5 ± 1.42.5 ± 1.6− 0.9 ± 1.6\< 0.000111093.4 ± 1.42.6 ± 1.5− 0.8 ± 1.6\< 0.0001 Straining19722.5 ± 1.51.9 ± 1.4− 0.6 ± 1.6\< 0.000110612.5 ± 1.51.9 ± 1.4− 0.6 ± 1.6\< 0.00019052.5 ± 1.51.9 ± 1.5− 0.6 ± 1.6\< 0.0001 Nocturia24282.5 ± 1.22.0 ± 1.0− 0.6 ± 1.0\< 0.000113032.5 ± 1.11.9 ± 1.0− 0.6 ± 1.0\< 0.000111182.6 ± 1.22.0 ± 1.0− 0.5 ± 1.0\< 0.0001QOL score25274.2 ± 0.93.0 ± 1.3− 1.3 ± 1.3\< 0.000113674.2 ± 0.92.9 ± 1.3− 1.3 ± 1.4\< 0.000111534.2 ± 0.93.0 ± 1.2− 1.2 ± 1.3\< 0.0001Total OABSS24745.7 ± 2.94.5 ± 2.7− 1.1 ± 2.3\< 0.000113335.6 ± 2.94.4 ± 2.7− 1.2 ± 2.4\< 0.000111345.7 ± 2.94.6 ± 2.7− 1.1 ± 2.1\< 0.0001 Frequency19511.0 ± 0.40.9 ± 0.4− 0.1 ± 0.6\< 0.000110471.0 ± 0.40.9 ± 0.4− 0.1 ± 0.6\< 0.00018981.0 ± 0.40.9 ± 0.5− 0.1 ± 0.6\< 0.0001 Nocturia24032.2 ± 0.81.8 ± 0.8− 0.4 ± 0.7\< 0.000112882.2 ± 0.81.8 ± 0.8− 0.4 ± 0.8\< 0.000111082.2 ± 0.81.9 ± 0.8− 0.4 ± 0.7\< 0.0001 Urgency19772.4 ± 1.31.8 ± 1.3− 0.6 ± 1.4\< 0.000110632.4 ± 1.31.8 ± 1.3− 0.6 ± 1.5\< 0.00019082.4 ± 1.41.9 ± 1.3− 0.5 ± 1.3\< 0.0001 Urinary incontinence11171.7 ± 1.21.3 ± 1.2− 0.4 ± 1.3\< 0.00015981.8 ± 1.21.3 ± 1.2− 0.5 ± 1.3\< 0.00015171.7 ± 1.21.3 ± 1.1− 0.4 ± 1.2\< 0.0001Residual urine volume (mL)139955.0 ± 68.637.8 ± 49.7− 17.2 ± 53.9\< 0.000175055.1 ± 70.737.6 ± 48.9− 17.5 ± 55.6\< 0.000164354.6 ± 66.137.7 ± 50.6− 16.8 ± 52.0\< 0.0001Data are presented as mean ± standard deviation unless otherwise indicated*IPSS* International Prostate Symptom Score, *OABSS* Overactive Bladder Symptom Score, *QOL* quality of life^a^One-sample *t*-test^b^Intermittency + weak stream + straining^c^Frequency + urgency + nocturia

### Improvement in Quality of Life Score {#Sec15}

The aggregated data for the 2527 patients in the effectiveness analysis set (*n* = 3144) who had paired QOL scores before and after silodosin administration are shown in Table [4](#Tab4){ref-type="table"}. The mean QOL scores before and after administration were 4.2 ± 0.9 and 3.0 ± 1.3, respectively, indicating a significant improvement (*P* \< 0.0001). In the subgroups of patients who had received an α~1~ blocker (tamsulosin or naftopidil) prior to silodosin treatment, similar significant improvements in the mean QOL were seen after switching (*P* \< 0.0001).

### Improvement in Overactive Bladder Symptom Score {#Sec16}

Between 1117 and 2474 patients in the effectiveness analysis set (*n* = 3144) had data for each OABSS symptom before and after the administration of silodosin and a value for those parameters that was not 0 (Table [4](#Tab4){ref-type="table"}). The mean total OABSS was 5.7 ± 2.9 at baseline and 4.5 ± 2.7 after silodosin, indicating a significant improvement (*P* \< 0.0001). All four symptoms of the OABSS showed a significant improvement from baseline with silodosin (*P* \< 0.0001). Significant improvements from baseline in total OABSS and all OABSS subscale scores were also seen in patients who had switched from tamsulosin or naftopidil (*P* \< 0.0001).

### Improvement in Residual Urine Volume {#Sec17}

In the effectiveness analysis set, 1399 of the 3144 patients had residual urine volume data at baseline and after the administration of silodosin (Table [4](#Tab4){ref-type="table"}). The mean residual urine volume at baseline was 55.0 ± 68.6 mL, decreasing to 37.8 ± 49.7 mL during silodosin treatment (*P* \< 0.0001). Similar reductions (improvements) in residual urine volume were seen in patients who had previously used tamsulosin or naftopidil before switching to silodosin (*P* \< 0.0001).

### Improvement in the Total IPSS According to Patient Background Factors {#Sec18}

The aggregated data of the total IPSS before and after the administration of silodosin according to patient background factors are shown in Table [5](#Tab5){ref-type="table"}. The mean total IPSS showed significant improvement during silodosin treatment in almost all subgroups containing at least 50 patients (*P* \< 0.001); the only exception was the group with mild symptoms (total IPSS ≤ 7) at baseline.Table 5Changes in total IPSS before and after silodosin administration in patient subgroups according to background factorsItems and categories*n*Before administrationAfter administrationChange*p* value^a^All patients251016.6 ± 6.712.5 ± 6.4− 4.1 ± 6.0\< 0.0001Age (years) \< 50813.3 ± 6.09.5 ± 6.8− 3.8 ± 5.00.0706 ≥ 50 and \< 6011417.2 ± 7.012.8 ± 6.7− 4.4 ± 5.1\< 0.0001 ≥ 60 and \< 7065216.6 ± 6.712.4 ± 6.4− 4.2 ± 5.9\< 0.0001 ≥ 70 and \< 80115316.5 ± 6.612.2 ± 6.2− 4.3 ± 6.1\< 0.0001 ≥ 8058316.9 ± 6.813.2 ± 6.9− 3.7 ± 5.9\< 0.0001 Non-elderly patients: \< 6535016.6 ± 6.812.2 ± 6.5− 4.3 ± 5.7\< 0.0001 Elderly patients: ≥ 65216016.7 ± 6.712.5 ± 6.4− 4.1 ± 6.0\< 0.0001BMI (kg/m^2^) \< 18.56115.4 ± 6.512.3 ± 6.2− 3.1 ± 5.0\< 0.0001 ≥ 18.5 and \< 25.0103516.6 ± 6.712.5 ± 6.6− 4.1 ± 6.0\< 0.0001 ≥ 25.0 and \< 30.042516.7 ± 7.012.6 ± 6.6− 4.1 ± 6.4\< 0.0001 ≥ 30.03715.8 ± 7.611.5 ± 7.2− 4.2 ± 7.40.0013 Unknown/unlisted95216.8 ± 6.612.5 ± 6.2− 4.3 ± 5.8\< 0.0001Prostate volume (mL) \< 40137616.3 ± 6.612.4 ± 6.3− 3.9 ± 6.0\< 0.0001 ≥ 4083717.1 ± 6.812.7 ± 6.3− 4.4 ± 6.2\< 0.0001 Unknown/unlisted29716.8 ± 7.012.3 ± 7.2− 4.6 ± 5.2\< 0.0001BPH duration \< 3 months0-------- ≥ 3 months and \< 1 year44716.2 ± 6.512.1 ± 6.5− 4.1 ± 5.9\< 0.0001 ≥ 1 year and \< 3 years71116.5 ± 6.811.9 ± 6.2− 4.6 ± 6.0\< 0.0001 ≥ 3 years125716.7 ± 6.712.9 ± 6.4− 3.8 ± 5.9\< 0.0001 Unknown/unlisted9518.9 ± 7.113.6 ± 7.8− 5.3 ± 6.3\< 0.0001PSA (ng/mL) ≤ 4.0172016.6 ± 6.612.5 ± 6.3− 4.1 ± 5.9\< 0.0001 \> 4.0 and ≤ 10.049516.4 ± 6.512.0 ± 6.2− 4.4 ± 6.2\< 0.0001 \> 10.07017.2 ± 7.914.0 ± 7.8− 3.2 ± 6.70.0001 Unknown/unlisted22517.3 ± 7.212.8 ± 7.5− 4.5 ± 5.8\< 0.0001α~1~ Blockers used prior to silodosin Tamsulosin135616.5 ± 6.812.3 ± 6.6− 4.2 ± 6.2\< 0.0001 Naftopidil114716.8 ± 6.512.7 ± 6.3− 4.1 ± 5.7\< 0.0001 Other1217.3 ± 6.313.3 ± 5.5− 3.9 ± 3.90.0051Concomitant drugs for LUTS other than α~1~ blockers Anticholinergics22616.8 ± 6.513.6 ± 6.6− 3.2 ± 5.1\< 0.0001 5α-Reductase inhibitor24415.3 ± 6.512.4 ± 6.4− 2.9 ± 5.9\< 0.0001 PDE5 inhibitor5020.3 ± 6.815.2 ± 5.0− 5.1 ± 5.8\< 0.0001 β~3~ Agonist17117.1 ± 6.813.3 ± 6.2− 3.8 ± 5.9\< 0.0001Total IPSS Mild: 0--72075.7 ± 1.46.7 ± 4.31.0 ± 4.40.0014 Moderate: 8--19146513.8 ± 3.310.8 ± 4.9− 3.0 ± 4.8\< 0.0001 Severe: 20--3583824.3 ± 3.616.9 ± 6.7− 7.4 ± 6.5\< 0.0001QOL score Mild: 0--10-------- Moderate: 2--4164714.6 ± 5.911.4 ± 5.9− 3.2 ± 5.6\< 0.0001 Severe: 5--686320.4 ± 6.614.5 ± 7.0− 5.9 ± 6.3\< 0.0001Total OABSS Mild: ≤ 5131214.0 ± 5.810.9 ± 5.7− 3.1 ± 5.4\< 0.0001 Moderate: 6--11107919.2 ± 6.313.9 ± 6.4− 5.2 ± 6.1\< 0.0001 Severe: ≥ 129624.4 ± 6.317.8 ± 9.0− 6.6 ± 8.8\< 0.0001Residual urine volume (mL) \< 50105916.0 ± 6.412.2 ± 6.3− 3.7 ± 5.9\< 0.0001 ≥ 50 and \< 10038717.6 ± 7.012.6 ± 6.6− 5.0 ± 6.8\< 0.0001 ≥ 10025617.4 ± 6.912.8 ± 6.3− 4.6 ± 6.2\< 0.0001 Unknown/unlisted80816.8 ± 6.812.7 ± 6.6− 4.1 ± 5.5\< 0.0001Data are presented as mean ± standard deviation unless otherwise indicated*BMI* body mass index, *BPH* benign prostatic hyperplasia, *IPSS* International Prostate Symptom Score, *LUTS* lower urinary tract symptoms, *OABSS* Overactive Bladder Symptom Score, *PDE* phosphodiesterase, *PSA* prostate-specific antigen, *QOL* quality of life^a^One sample t-test

Discussion {#Sec19}
==========

The clinical guidelines for BPH in Japan recommend α~1~ blockers as a first-line drug therapy for BPH \[[@CR3]\]. Although silodosin has been compared with tamsulosin or naftopidil in crossover or parallel studies \[[@CR5]--[@CR7]\], evidence concerning the effect of switching between α~1~ blockers is currently limited. We expected that this survey would demonstrate the specific patient characteristics suitable for switching to silodosin from other α~1~ blockers and the effect of the switching.

As for the safety profile, the incidence of ADRs with silodosin was 8.1% in this post-marketing surveillance, indicating a slightly lower rate compared with the aggregated results (11.3%) \[[@CR8]\] in the previous post-marketing surveys \[[@CR1], [@CR2]\]. ADRs that occurred at an incidence of ≥ 0.5% included ejaculation disorder, retrograde ejaculation, diarrhoea, dizziness, and nasal congestion. No new safety signals were identified, as all of the common ADRs in our analysis were consistent with those in the previous surveys.

Consistent with the previous post-marketing surveys, the incidence of ADRs was significantly higher in non-elderly patients (17.1%) than in elderly patients (6.6%). A total of 271 patients developed ADRs, and the most common ADRs were ejaculation disorder (*n* = 52) and retrograde ejaculation (*n* = 47), events that are likely to be more frequent in non-elderly patients as shown in previous post-marketing data. The age-related incidence of ADRs based on 10-year increments was also investigated, and the result indicated a lower incidence of ADRs with more advancing age, as has been shown previously.

Since silodosin was launched, a number of new therapeutic agents for overactive bladder (OAB) and BPH have become available, including anticholinergics, 5α-reductase inhibitor, PDE5 inhibitor, and β~3~ agonist. The incidence of ADRs in patients taking these agents concomitantly with silodosin (7.6%) was not significantly different from that in silodosin recipients not taking concomitant BPH therapy (8.3%). The incidence of ADRs according to the type of concomitant drugs was as follows: anticholinergics 7.7%; 5α-reductase inhibitor 6.9%; PDE5 inhibitor 10.1%; and β~3~ agonist 5.6%. Although the incidence of silodosin ADRs was slightly higher with concomitant use of a PDE5 inhibitor than with other drug classes, the number of patients receiving this combination was small (*n* = 69). Therefore, more data from a larger cohort of patients are needed.

As for the effectiveness profile, the mean change in total IPSS after switching to silodosin was − 4.1 ± 6.0, indicating a significant improvement in symptoms. Furthermore, significant improvements were observed in all effectiveness outcome measures, including the seven symptoms of the IPSS, the IPSS voiding symptom score, the IPSS storage symptom score, the QOL score, the total OABSS, the four symptoms of the OABSS, and residual urine volume. Similar improvements were observed in patients who had previously received tamsulosin or naftopidil before switching to silodosin, indicating no difference depending on the types of prior therapeutic drugs. The results suggested that switching to silodosin, which has high α~1A~-receptor selectivity, could be a treatment option for patients with a low level of satisfaction with the treatment.

With the exception of patients who had mild symptoms (total IPSS ≤ 7) at baseline, significant improvements in total IPSS were seen after switching in all subgroups containing at least 50 patients. Thus, switching to silodosin improved the total IPSS in most patients, regardless of background factors. Patients whose symptoms were of mild severity in the total IPSS during their initial α~1~ blocker treatment did not show further improvement after switching to silodosin. Therefore, total IPSS at the time of switching can be a predictor of the effect of the switching.

This study was conducted to investigate the effectiveness and safety of silodosin in patients with BPH who had not achieved satisfactory symptom control with other α~1~ blockers in routine clinical practice. The results confirmed the safety of silodosin, consistent with previous post-marketing surveys such as the drug use results survey, and showed there was no increase in the incidence of ADRs with the use of any type of concomitant drug for LUTS treatment. Moreover, significant improvements in effectiveness were observed in all outcome measures, including the IPSS, the QOL score and OABSS.
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This survey was conducted in accordance with good post-marketing study practice in Japan.
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According to good post-marketing study practice in Japan, informed consent was not required for this post-marketing study. As such, informed consent was not obtained from individual participants included in the study.
